Pfizer has announced the results from randomized phase-III trial of Sutent (sunitinib malate), in patients with advanced pancreatic islet cell tumors. Study demonstrated that median progression-free survival was
Insmed has declared the results of phase-II clinical trial evaluating IPLEX (mecasermin rinfabate) in patients with myotonic muscular dystrophy (MMD). The randomized, double-blind, placebo-controlled trial conducted in 13
Shamrock has received a phase-I Small Business Innovation Research (SBIR) grant to develop Wide Angle X-ray Scattering (WAXS) for Drug Discovery. It is funded by the National Institute
Antigenics has announced that Brain Tumor Research Center at the University of California (UCSF), has expanded phase-II clinical trial of Oncophage (vitespen) for glioma. The trial will now
OXiGENE has initiated the phase-II study of vascular disrupting agent drug candidate, Zybrestat for ophthalmology in patients with polypoidal choroidal vasculopathy (PCV). The phase-II favor study is a
Zila has entered into a merger agreement with Tolmar, a privately-held pharmaceutical research, development, manufacturing and commercial operations company. Under the terms of the agreement, Tolmar will acquire
AstraZeneca and Bristol-Myers’ marketing authorisation application for Onglyza (saxagliptin) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), for Onglyza. It is
Teva and Active Biotech have announced the completion of patient enrollment for the second pivotal phase-III clinical trial, BRAVO. It is intended to evaluate oral once-daily immunomodulating compound,
Inotek has reported positive top-line results from phase 1/2 randomized, double-blind, placebo-controlled clinical trial of INO-8875, in patients with glaucoma. The study showed that the treatment with INO-8875
Novartis’ new study demonstrated that treatment with Afinitor (everolimus) tablets, in combination with Sandostatin LAR (octreotide acetate suspension for injection) and Afinitor monotherapy, may have the potential to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.